Top ▲

Peroxisome proliferator-activated receptor-γ

Click here for help

Target id: 595

Nomenclature: Peroxisome proliferator-activated receptor-γ

Systematic Nomenclature: NR1C3

Family: 1C. Peroxisome proliferator-activated receptors

Contents:

Gene and Protein Information Click here for help
Species AA Chromosomal Location Gene Symbol Gene Name Reference
Human 505 3p25.2 PPARG peroxisome proliferator activated receptor gamma 3,42,107
Mouse 505 6 53.41 cM Pparg peroxisome proliferator activated receptor gamma 141
Rat 505 4q42 Pparg peroxisome proliferator-activated receptor gamma 44
Previous and Unofficial Names Click here for help
PPARG1 | PPARG2 | PPARgamma | nuclear receptor subfamily 1 group C member 3 | PPARgamma2
Database Links Click here for help
Alphafold P37231 (Hs), P37238 (Mm), O88275 (Rn)
CATH/Gene3D 3.30.50.10
ChEMBL Target CHEMBL235 (Hs), CHEMBL2459 (Mm), CHEMBL4797 (Rn)
DrugBank Target P37231 (Hs)
Ensembl Gene ENSG00000132170 (Hs), ENSMUSG00000000440 (Mm), ENSRNOG00000008839 (Rn)
Entrez Gene 5468 (Hs), 19016 (Mm), 25664 (Rn)
Human Protein Atlas ENSG00000132170 (Hs)
KEGG Gene hsa:5468 (Hs), mmu:19016 (Mm), rno:25664 (Rn)
OMIM 601487 (Hs)
Orphanet ORPHA117964 (Hs)
Pharos P37231 (Hs)
RefSeq Nucleotide NM_005037 (Hs), NM_138711 (Hs), NM_015869 (Hs), NM_138712 (Hs), NM_011146 (Mm), NM_001127330 (Mm), NM_001308352 (Mm), NM_001308354 (Mm), NM_001145366 (Rn), NM_013124 (Rn), NM_001145367 (Rn)
RefSeq Protein NP_056953 (Hs), NP_619725 (Hs), NP_001120802 (Mm), NP_035276 (Mm), NP_037256 (Rn)
SynPHARM 83093 (in complex with bexarotene)
8005 (in complex with diclofenac)
6362 (in complex with farglitazar)
6338 (in complex with GW0072)
6369 (in complex with GW409544)
8003 (in complex with GW9662)
6364 (in complex with indomethacin)
78800 (in complex with MRL20)
6359 (in complex with netoglitazone)
6344 (in complex with nTzDpa)
6339 (in complex with ragaglitazar)
82690 (in complex with resveratrol)
6357 (in complex with rosiglitazone)
79481 (in complex with rosiglitazone)
UniProtKB P37231 (Hs), P37238 (Mm), O88275 (Rn)
Wikipedia PPARG (Hs)
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Peroxisome proliferator-activated receptor-γ (ligand binding domain)
PDB Id:  1NYX
Ligand:  ragaglitazar
Resolution:  2.65Å
Species:  Human
References:  32
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of PPARgamma in complex with compound (R)-16
PDB Id:  6Y3U
Ligand:  (R)-16 [PMID: 32267688]
Resolution:  2.62Å
Species:  Human
References:  46
Natural/Endogenous Ligands Click here for help
15-deoxy-Δ-12,14-prostaglandin J2
linoleic acid
Comments: Fatty acids, prostaglandin J2 and eisosanoids are reported natural ligands

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
farglitazar Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Partial agonist 7.5 pKd 50,135
⤷ pKd 7.5 [50,135]
rosiglitazone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Full agonist 7.4 pKd 50,74,134
⤷ pKd 7.4 [50,74,134]
indomethacin Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Partial agonist 7.4 pKd 37,74
⤷ pKd 7.4 [37,74]
[125I]SB-236636 Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Full agonist 7.1 pKd 134
⤷ pKd 7.1 [134]
GW2331 Small molecule or natural product Ligand has a PDB structure ? Full agonist 6.5 pKd 62
⤷ pKd 6.5 [62]
[3H]GW2331 Small molecule or natural product Ligand is labelled Ligand is radioactive ? Full agonist 6.5 pKd 62
⤷ pKd 6.5 [62]
MK-0767 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.5 pKd 87-88
⤷ pKd 6.5 [87-88]
PAT5A Small molecule or natural product Hs Partial agonist 6.3 pKd 83,125
⤷ pKd 6.3 [83,125]
netoglitazone Small molecule or natural product Hs Full agonist 6.3 pKd 102
⤷ pKd 6.3 [102]
linoleic acid Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Hs Full agonist 5.3 pKd 37,135
⤷ pKd 5.3 [37,135]
BADGE Small molecule or natural product Hs Full agonist 4.0 pKd 9,129
⤷ pKd 4.0 [9,129]
GW1929 Small molecule or natural product Ligand has a PDB structure Hs Full agonist 8.8 pKi 12
⤷ pKi 8.8 [12]
L-796449 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 8.7 pKi 7
⤷ pKi 8.7 [7]
GW7845 Small molecule or natural product Hs Full agonist 8.4 pKi 22,50
⤷ pKi 8.4 [22,50]
bardoxolone Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Partial agonist 8.0 pKi 127
⤷ pKi 8.0 [127]
L-783483 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist 7.8 pKi 7
⤷ pKi 7.8 [7]
L-165461 Small molecule or natural product Hs Full agonist 7.8 pKi 7
⤷ pKi 7.8 [7]
AD5075 Small molecule or natural product Hs Full agonist 7.7 pKi 7-8
⤷ pKi 7.7 [7-8]
[3H]AD5075 Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Full agonist 7.7 pKi 6
⤷ pKi 7.7 [6]
rosiglitazone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Agonist 6.9 pKi 79
⤷ pKi 6.9 (Ki 1.2x10-7 M) [79]
FMOC-L-Leucine Small molecule or natural product Hs Partial agonist 6.0 pKi 104
⤷ pKi 6.0 [104]
troglitazone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Full agonist 5.8 pKi 6
⤷ pKi 5.8 (Ki 1.585x10-6 M) [6]
GW409544 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist 9.6 pEC50 49,130
⤷ pEC50 9.6 [49,130]
(R)-16 [PMID: 32267688] Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 8.8 pEC50 46
⤷ pEC50 8.8 (EC50 1.6x10-9 M) [46]
Description: Measuring nuclear receptor modulation in Gal4-hybrid reporter gene assays conducted in transiently transfected HEK293T cells.
edaglitazone Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 7.4 pEC50 30
⤷ pEC50 7.4 (EC50 3.56x10-8 M) [30]
Description: Measuring agonist-induced cofactor recruitment.
elafibranor Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 7.3 pEC50 108
⤷ pEC50 7.3 (EC50 4.7x10-8 M) [108]
reglitazar Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.1 pEC50 118
⤷ pEC50 7.1 [118]
chiglitazar Small molecule or natural product Approved drug Click here for species-specific activity table Hs Agonist 7.1 pEC50 77
⤷ pEC50 7.1 (EC50 8x10-8 M) [77]
Description: Measuring transactivation by human PPARδ in U-2OS cells
MK-0767 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.0 pEC50 31
⤷ pEC50 7.0 [31]
lanifibranor Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 6.7 pEC50 10
⤷ pEC50 6.7 (EC50 2.06x10-7 M) [10]
MDG 548 Small molecule or natural product Immunopharmacology Ligand Hs Agonist 6.7 pEC50 89
⤷ pEC50 6.7 (EC50 2.15x10-7 M) [89]
Description: Measured by TR-FRET analysis.
triple modulator 10 [PMID: 29878767] Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Partial agonist 6.5 pEC50 113
⤷ pEC50 6.5 (EC50 3x10-7 M) [113]
GW9578 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.0 pEC50 13
⤷ pEC50 6.0 [13]
seladelpar Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Agonist <6.0 pEC50 139
⤷ pEC50 <6.0 (EC50 >1x10-6 M) [139]
Description: Agonist activity determined by cell based transactivation assay.
zafirlukast Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Agonist 5.6 pEC50 113
⤷ pEC50 5.6 (EC50 2.44x10-6 M) [113]
ciglitazone Small molecule or natural product Hs Full agonist 4.6 pEC50 50
⤷ pEC50 4.6 [50]
MRL24 Small molecule or natural product Ligand has a PDB structure Hs Partial agonist 9.0 pIC50 1
⤷ pIC50 9.0 (IC50 1x10-9 M) In vitro hPPARγ binding [1]
MRL20 Small molecule or natural product Ligand has a PDB structure Hs Partial agonist 8.7 pIC50 1
⤷ pIC50 8.7 (IC50 2x10-9 M) In vitro hPPARγ binding [1]
SB-219994 Small molecule or natural product Hs Full agonist 8.7 pIC50 134
⤷ pIC50 8.7 [134]
LY-510929 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 8.0 pIC50 131,146
⤷ pIC50 8.0 [131,146]
AD-5061 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.7 pIC50 109-110
⤷ pIC50 7.7 [109-110]
TZD18 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 7.2 pIC50 45
⤷ pIC50 7.2 [45]
L-764406 Small molecule or natural product Hs Partial agonist 7.2 pIC50 34
⤷ pIC50 7.2 [34]
ragaglitazar Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist 7.0 pIC50 20,32,97
⤷ pIC50 7.0 [20,32,97]
GW0072 Small molecule or natural product Ligand has a PDB structure Hs Partial agonist 7.0 pIC50 95
⤷ pIC50 7.0 [95]
nTzDpa Small molecule or natural product Ligand has a PDB structure Hs Partial agonist 6.5 pIC50 8
⤷ pIC50 6.5 [8]
15-deoxy-Δ-12,14-prostaglandin J2 Small molecule or natural product Ligand is endogenous in the given species Hs Full agonist 6.3 pIC50 61-62,90,93,119
⤷ pIC50 6.3 [61-62,90,93,119]
troglitazone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Full agonist 6.3 pIC50 50,134
⤷ pIC50 6.3 (IC50 5.012x10-7 M) [50,134]
LY-465608 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 6.3 pIC50 11
⤷ pIC50 6.3 [11]
pioglitazone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Full agonist 6.2 pIC50 50,110,134
⤷ pIC50 6.2 [50,110,134]
SB-219993 Small molecule or natural product Hs Full agonist 5.5 pIC50 134
⤷ pIC50 5.5 [134]
VCE-004.3 Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Agonist 5.5 pIC50 27
⤷ pIC50 5.5 (IC50 3.5x10-6 M) [27]
tirotundin Small molecule or natural product Hs Agonist 4.6 pIC50 78
⤷ pIC50 4.6 (IC50 2.7x10-5 M) [78]
Description: Measuring PPARγ transactivation in response to compound binding directly to the receptor's ligand binding domain.
tagitinin A Small molecule or natural product Hs Agonist 4.3 pIC50 78
⤷ pIC50 4.3 (IC50 5.5x10-5 M) [78]
Description: Measuring PPARγ transactivation in response to compound binding directly to the receptor's ligand binding domain.
mesalazine Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Full agonist 1.8 pIC50 106
⤷ pIC50 1.8 [106]
DRF 2519 Small molecule or natural product ? Full agonist - - 19
⤷ [19]
ibuprofen Small molecule or natural product Approved drug Immunopharmacology Ligand ? Full agonist - - 57,65
⤷ [57,65]
diclofenac Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand ? Partial agonist - - 65
⤷ [65]
COOH Small molecule or natural product ? Full agonist - - 15,68
⤷ [15,68]
LG100754 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Full agonist - - 17,38
⤷ [17,38]
View species-specific agonist tables
Agonist Comments
Various endogenous fatty acid agonists , with pIC50 values of approximately 6, have been reported [130].
VCE-004.3 does not activate PPARα- or PPARδ-mediated transcription [27].
Antagonists Click here for help
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
resveratrol Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Antagonist 5.8 pKd 14
⤷ pKd 5.8 (Kd 1.4x10-6 M) [14]
T0070907 Small molecule or natural product Ligand has a PDB structure Hs Antagonist 9.0 pKi 71
⤷ pKi 9.0 (Ki 1x10-9 M) [71]
CDDO-Me Small molecule or natural product Hs Antagonist 6.9 pKi 127
⤷ pKi 6.9 (Ki 1.3x10-7 M) [127]
diclofenac Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Antagonist 6.2 pKi 2
⤷ pKi 6.2 [2]
BADGE Small molecule or natural product Hs Antagonist 4.0 pKi 129
⤷ pKi 4.0 [129]
GW9662 Small molecule or natural product Ligand has a PDB structure Hs Irreversible inhibition 8.1 pIC50 73
⤷ pIC50 8.1 [73]
bexarotene Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist ~5.5 pIC50 80
⤷ pIC50 ~5.5 (IC50 ~3x10-6 M) [80]
Description: Measured using a TR-FRET competitive displacement assay.
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound 10 [O'Mahony et al., 2022] Small molecule or natural product Ligand has a PDB structure Hs Binding 7.6 pIC50 94
⤷ pIC50 7.6 (IC50 2.4x10-8 M) [94]
Description: PPARγ binding
Immunopharmacology Comments
PPARγ agonists have anti-inflammatory effects. Full PPARγ agonists can cause undesireable weight gain, but partial agonists are devoid of this adverse effect and retain the anti-inflammatory effects of PPARγ modulation.
The PPARγ agonist MDG 548 boosts the inflammatory phenotype of microglia and enhances their phagocytic capacity [69]. These actions are proposed to mediate the compound's neuroprotective effect.
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process:  Immune regulation
Immuno Process:  Immune system development
Immuno Process:  Cytokine production & signalling
Immuno Process:  Antigen presentation
Immuno Process:  Cellular signalling
DNA Binding Click here for help
Structure:  Heterodimer, RXR partner
HRE core sequence:  5'-AACTAGGNCA A AGGTCA-3'
Response element:  DR1
Co-binding Partners Click here for help
Name Interaction Effect Reference
RXR Physical, Functional DNA binding 63
Main Co-regulators Click here for help
Name Activity Specific Ligand dependent AF-2 dependent Comments References
WWTR1 Co-repressor No Yes No 52
SCAND1 Co-activator Yes Yes Yes 16
NCOA4 Co-activator Yes No No 48
PPARGC1A Co-activator No Yes Yes 53-54,64,96,98
PPARGC1B Co-activator No Yes Yes 43,58,64,96,98
CREBBP Co-activator No Yes Yes 84,140
EP300 Co-activator No Yes Yes 41
CITED2 Co-activator No Yes Yes 120
NCOR2 Co-repressor Yes No No 56,136
NCOA7 Co-activator No No No 117
NCOA6 Co-activator No Yes Yes 100,142
PRMT2 Co-activator No Yes No 99
TGS1 Co-activator No Yes No 143
NCOA1 Co-activator No No No 101,140,143
NCOA2 Co-activator No Yes Yes 72
NCOA3 Co-activator No No Yes 85
NRIP1 Co-repressor No Yes Yes 123
SMARCA1 Co-activator No No No 25,76
SAFB Co-repressor Yes No No 24
NCOR1 Co-repressor No No No 29,136,138
MED1 Co-activator No Yes Yes 133,144
Main Target Genes Click here for help
Name Species Effect Technique Comments References
Apoa2: apolipoprotein A-II Mouse Activated EMSA, ChIP 126
Fabp4: fatty acid binding protein 4 Mouse Activated ChIP 121
Pck1: phosphoenolpyruvate carboxykinase 1 Mouse Activated Transient transfection, EMSA 122
Ucp1: uncoupling protein 1 Mouse Activated Transient transfection 116,132
Acsf2: acyl CoA-synthetase Mouse Activated EMSA, Other 82,115
Lpl: lipoprotein lipase Mouse Activated EMSA 114
Slc27a: solute carrier family 27 member 1 Mouse Activated Transient transfection, EMSA 40
Tissue Distribution Click here for help
Adipose tissues, lymphoid tissues, colon, liver and heart
Species:  Human
Technique:  Northern Blot, Western Blot, Immunohistochemistry
References:  29
Tissue Distribution Comments
Expression of Ppar-γ in mice and rats has been detected in adipose, lymphoid tissues and the colon.
Functional Assays Click here for help
BADGE: adipogenesis assay
Species:  Mouse
Tissue:  3T3-L1, 3T3-F442A cells
Response measured:  staining of lipids with oil Red O, adipocyte-specific markers
References:  129
Induction of apoptotic cell death
Species:  Rat
Tissue:  C6 glioma cells
Response measured:  lipogenesis by TUNEL staining
References:  43
Adipocyte differentiation assay
Species:  Human
Tissue:  C3H10T1/2 cells
Response measured:  triglyceride accumulation in adipocytes by adding lipoprotein lipase and glycerol phosphatase oxidase
References:  12,75
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0004185 abnormal adipocyte glucose uptake PMID: 19117549 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0000013 abnormal adipose tissue distribution PMID: 15254591 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0000013 abnormal adipose tissue distribution PMID: 17003330 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified		 MGI:97747  MP:0000013 abnormal adipose tissue distribution PMID: 15919792 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0000003 abnormal adipose tissue morphology PMID: 15716267 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6		 MGI:2450254  MGI:97747  MP:0005666 abnormal adipose tissue physiology PMID: 15070754 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR		 MGI:97747  MP:0002459 abnormal B cell physiology PMID: 10549291 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001993 abnormal blinking PMID: 16845470 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0001777 abnormal body temperature regulation PMID: 14603033 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0000168 abnormal bone marrow development PMID: 15067317 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0002397 abnormal bone marrow morphology PMID: 15067317 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0008271 abnormal bone ossification PMID: 15067317 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0003795 abnormal bone structure PMID: 19117549 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0002971 abnormal brown adipose tissue morphology PMID: 14660788 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0002971 abnormal brown adipose tissue morphology PMID: 15249658 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0002971 abnormal brown adipose tissue morphology PMID: 17921248 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0002971 abnormal brown adipose tissue morphology PMID: 17921248 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6		 MGI:2450254  MGI:97747  MP:0009116 abnormal brown fat cell morphology PMID: 15070754 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0009116 abnormal brown fat cell morphology PMID: 15716267 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0009116 abnormal brown fat cell morphology PMID: 17921248 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0009135 abnormal brown fat cell size PMID: 14660788 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0000130 abnormal cancellous bone morphology PMID: 15067317 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA		 MGI:97747  MP:0005076 abnormal cell differentiation PMID: 10549291  15067317 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0005076 abnormal cell differentiation PMID: 10549291 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0005076 abnormal cell differentiation PMID: 19117549 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0004560 abnormal chorionic plate morphology PMID: 10549290 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0001573 abnormal circulating alanine transaminase level PMID: 14603033 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0009165 abnormal endocrine pancreas morphology PMID: 15254591 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 15254591 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 17003330 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 17465682 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 14536066 
Dok1tm1Yyam|Ppargtm1Laz Dok1tm1Yyam/Dok1tm1Yyam,Ppargtm1Laz/Ppargtm1Laz
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6		 MGI:893587  MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 18204460 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0009115 abnormal fat cell morphology PMID: 10549291  15067317 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0008788 abnormal fetal cardiomyocyte morphology PMID: 10549290 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001406 abnormal gait PMID: 16845470 
Pparg+|Ppargtm1Rev Ppargtm1Rev/Pparg+
involves: 129S4/SvJae * C57BL/6J		 MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 10675354 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 14603033 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 17003330 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified		 MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 15919792 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 17465682 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0002078 abnormal glucose homeostasis PMID: 14536066 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0005335 abnormal gonadal fat pad morphology PMID: 15254591 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0005335 abnormal gonadal fat pad morphology PMID: 17003330 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA		 MGI:97747  MP:0000267 abnormal heart development PMID: 10549291 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0000607 abnormal hepatocyte morphology PMID: 17921248 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR		 MGI:97747  MP:0001800 abnormal humoral immune response PMID: 10549291 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0005336 abnormal inguinal fat pad morphology PMID: 15254591 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0003564 abnormal insulin secretion PMID: 17465682 
Ppargtm1.2Mtz|Tg(Krt1-10-cre)1Pcn Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Krt1-10-cre)1Pcn/0
involves: C57BL/6 * SJL		 MGI:3629071  MGI:97747  MP:0002655 abnormal keratinocyte morphology PMID: 16751185 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0002118 abnormal lipid homeostasis PMID: 17003330 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0002118 abnormal lipid homeostasis PMID: 17465682 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0000598 abnormal liver morphology PMID: 17465682 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0001392 abnormal locomotor activity PMID: 17465682 
Ppargtm1.1Gonz|Tg(Mx1-cre)1Cgn Ppargtm1.1Gonz/Ppargtm1.1Gonz,Tg(Mx1-cre)1Cgn/?
involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N		 MGI:2176072  MGI:97747  MP:0002451 abnormal macrophage physiology PMID: 11909955 
Ppargtm1Gonz|Tg(MMTV-cre)1Mam Ppargtm1Gonz/Ppargtm1Gonz,Tg(MMTV-cre)1Mam/?
involves: 129X1/SvJ * FVB		 MGI:2176162  MGI:97747  MP:0006269 abnormal mammary gland growth during pregnancy PMID: 11884400 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001516 abnormal motor coordination/ balance PMID: 16845470 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0004130 abnormal muscle cell glucose uptake PMID: 15716267 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0000278 abnormal myocardial fiber morphology PMID: 10549290 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0002189 abnormal myocardial trabeculae morphology PMID: 10549290 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0008395 abnormal osteoblast differentiation PMID: 15067317 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0005215 abnormal pancreatic islet morphology PMID: 17465682 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:97747  MP:0005215 abnormal pancreatic islet morphology PMID: 17465682 
Ppargtm1.1Mtz Ppargtm1.1Mtz/Ppargtm1.1Mtz
involves: C57BL/6		 MGI:97747  MP:0001712 abnormal placenta development PMID: 15070754 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0001716 abnormal placenta labyrinth morphology PMID: 10549290 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA		 MGI:97747  MP:0001716 abnormal placenta labyrinth morphology PMID: 10549291 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0008803 abnormal placental labyrinth vasculature morphology PMID: 10549290 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA		 MGI:97747  MP:0008803 abnormal placental labyrinth vasculature morphology PMID: 10549291 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0001711 abnormal placenta morphology PMID: 10549290 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0003088 abnormal prepulse inhibition PMID: 16845470 
Atp2b2+|Atp2b2m1Mae|Pparg+|Ppargtm2Mae Atp2b2m1Mae/Atp2b2+,Ppargtm2Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0003088 abnormal prepulse inhibition PMID: 16845470 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001961 abnormal reflex PMID: 16845470 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0005164 abnormal response to injury PMID: 11889020 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR		 MGI:97747  MP:0005164 abnormal response to injury PMID: 11159886 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0002792 abnormal retinal vasculature morphology PMID: 17003451 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0000759 abnormal skeletal muscle morphology PMID: 17003330 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0000759 abnormal skeletal muscle morphology PMID: 17465682 
Ppargtm1.2Mtz|Tg(Krt1-10-cre)1Pcn Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Krt1-10-cre)1Pcn/0
involves: C57BL/6 * SJL		 MGI:3629071  MGI:97747  MP:0002060 abnormal skin morphology PMID: 16751185 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0000187 abnormal triglyceride level PMID: 17003330 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0005033 abnormal trophoblast giant cells PMID: 10549290 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0005031 abnormal trophoblast layer morphology PMID: 10549290 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001490 abnormal vibrissae reflex PMID: 16845470 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0003491 abnormal voluntary movement PMID: 16845470 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0001781 abnormal white adipose tissue amount PMID: 14660788 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0001781 abnormal white adipose tissue amount PMID: 17003330 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0002970 abnormal white adipose tissue morphology PMID: 15249658 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0002970 abnormal white adipose tissue morphology PMID: 15716267 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0002970 abnormal white adipose tissue morphology PMID: 17921248 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0005670 abnormal white adipose tissue physiology PMID: 15249658 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified		 MGI:97747  MP:0005670 abnormal white adipose tissue physiology PMID: 15919792 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6		 MGI:2450254  MGI:97747  MP:0009117 abnormal white fat cell morphology PMID: 15070754 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0009117 abnormal white fat cell morphology PMID: 17921248 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0009132 abnormal white fat cell size PMID: 17921248 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0006358 absent pinna reflex PMID: 16845470 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0006359 absent startle reflex PMID: 16845470 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0008843 absent subcutaneous adipose tissue PMID: 17921248 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001393 ataxia PMID: 16845470 
Ppargtm1.1Gonz|Tg(Myhca-cre)1Abel Ppargtm1.1Gonz/Ppargtm1.1Gonz,Tg(Myhca-cre)1Abel/0
involves: 129X1/SvJ * FVB		 MGI:2182090  MGI:97747  MP:0001625 cardiac hypertrophy PMID: 16051889 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0004893 decreased adiponectin level PMID: 15249658 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0004893 decreased adiponectin level PMID: 15716267 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0004893 decreased adiponectin level PMID: 17003330 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0004893 decreased adiponectin level PMID: 17003330 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified		 MGI:97747  MP:0004893 decreased adiponectin level PMID: 15919792 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0004893 decreased adiponectin level PMID: 17465682 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:97747  MP:0004893 decreased adiponectin level PMID: 17465682 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0006086 decreased body mass index PMID: 19117549 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001265 decreased body size PMID: 16845470 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0001262 decreased body weight PMID: 14603033 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0001262 decreased body weight PMID: 15249658 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0001262 decreased body weight PMID: 15716267 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0001262 decreased body weight PMID: 17003330 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0001262 decreased body weight PMID: 19117549 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0001780 decreased brown adipose tissue amount PMID: 14603033 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0001780 decreased brown adipose tissue amount PMID: 14660788 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6		 MGI:2450254  MGI:97747  MP:0001780 decreased brown adipose tissue amount PMID: 15070754 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0001780 decreased brown adipose tissue amount PMID: 10549291 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0009125 decreased brown fat cell lipid droplet size PMID: 15249658 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0009128 decreased brown fat cell number PMID: 14660788 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0009137 decreased brown fat lipid droplet number PMID: 15249658 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0005179 decreased circulating cholesterol level PMID: 19117549 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0002702 decreased circulating free fatty acid level PMID: 14536066 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0002727 decreased circulating insulin level PMID: 17465682 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0002727 decreased circulating insulin level PMID: 10549291 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0005668 decreased circulating leptin level PMID: 15249658 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0005668 decreased circulating leptin level PMID: 14536066 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0002644 decreased circulating triglyceride level PMID: 14536066 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0002644 decreased circulating triglyceride level PMID: 19117549 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0003910 decreased eating behavior PMID: 10549291 
Ppargtm1Lja Ppargtm1Lja/Ppargtm1Lja
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0001698 decreased embryo size PMID: 15716267 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6		 MGI:2450254  MGI:97747  MP:0009289 decreased epididymal fat pad weight PMID: 15070754 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0009269 decreased fat cell size PMID: 17003330 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0009283 decreased gonadal fat pad weight PMID: 15249658 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0009283 decreased gonadal fat pad weight PMID: 17921248 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0009283 decreased gonadal fat pad weight PMID: 17921248 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0010053 decreased grip strength PMID: 16845470 
Ppargtm1.1Gonz|Tg(Myhca-cre)1Abel Ppargtm1.1Gonz/Ppargtm1.1Gonz,Tg(Myhca-cre)1Abel/0
involves: 129X1/SvJ * FVB		 MGI:2182090  MGI:97747  MP:0005333 decreased heart rate PMID: 16051889 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0009293 decreased inguinal fat pad weight PMID: 15249658 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0009295 decreased interscapular fat pad weight PMID: 14660788 
Ppargtm1Gonz|Tg(MMTV-cre)1Mam Ppargtm1Gonz/Ppargtm1Gonz,Tg(MMTV-cre)1Mam/?
involves: 129X1/SvJ * FVB		 MGI:2176162  MGI:97747  MP:0001935 decreased litter size PMID: 11884400 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0009356 decreased liver triglyceride level PMID: 17465682 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6		 MGI:2450254  MGI:97747  MP:0005459 decreased percent body fat PMID: 15070754 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0010379 decreased respiratory quotient PMID: 17465682 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0009305 decreased retroperitoneal fat pad weight PMID: 15249658 
Atp2b2+|Atp2b2m1Mae|Pparg+|Ppargtm2Mae Atp2b2m1Mae/Atp2b2+,Ppargtm2Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001489 decreased startle reflex PMID: 16845470 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0008844 decreased subcutaneous adipose tissue amount PMID: 17921248 
Ppargtm1.1Unc Ppargtm1.1Unc/Ppargtm1.1Unc
involves: 129S6/SvEvTac * C57BL/6J		 MGI:97747  MP:0002843 decreased systemic arterial blood pressure PMID: 19884495 
Pparg+|Ppargtm1.1Unc Ppargtm1.1Unc/Pparg+
involves: 129S6/SvEvTac * C57BL/6J		 MGI:97747  MP:0002843 decreased systemic arterial blood pressure PMID: 19884495 
Pparg+|Ppargtm1Uls Ppargtm1Uls/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0010025 decreased total body fat amount PMID: 15231871 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0010025 decreased total body fat amount PMID: 15716267 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0010025 decreased total body fat amount PMID: 17003330 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified		 MGI:97747  MP:0010025 decreased total body fat amount PMID: 15919792 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0010025 decreased total body fat amount PMID: 10549291 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0008907 decreased total fat pad weight PMID: 19117549 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0005318 decreased triglyceride level PMID: 17465682 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0001783 decreased white adipose tissue amount PMID: 14603033 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0001783 decreased white adipose tissue amount PMID: 15249658 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0001783 decreased white adipose tissue amount PMID: 15716267 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0009131 decreased white fat cell number PMID: 15249658 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0009133 decreased white fat cell size PMID: 15249658 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0009254 disorganized pancreatic islets PMID: 17465682 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA		 MGI:97747  MP:0003984 embryonic growth retardation PMID: 10549291 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0006207 embryonic lethality during organogenesis PMID: 10549290 
Ppargtm1Lja Ppargtm1Lja/Ppargtm1Lja
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0006207 embryonic lethality during organogenesis PMID: 15716267 
Ppargtm1.1Mtz Ppargtm1.1Mtz/Ppargtm1.1Mtz
involves: C57BL/6		 MGI:97747  MP:0006207 embryonic lethality during organogenesis PMID: 15070754 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA		 MGI:97747  MP:0006207 embryonic lethality during organogenesis PMID: 10549291 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0000599 enlarged liver PMID: 14603033 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0000599 enlarged liver PMID: 14660788 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0000599 enlarged liver PMID: 17921248 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0000599 enlarged liver PMID: 17921248 
Ppargtm1.1Gonz|Tg(Myhca-cre)1Abel Ppargtm1.1Gonz/Ppargtm1.1Gonz,Tg(Myhca-cre)1Abel/0
involves: 129X1/SvJ * FVB		 MGI:2182090  MGI:97747  MP:0004564 enlarged myocardial fiber PMID: 16051889 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0001661 extended life span PMID: 19117549 
Ppargtm1Gonz|Tg(MMTV-cre)1Mam Ppargtm1Gonz/Ppargtm1Gonz,Tg(MMTV-cre)1Mam/?
involves: 129X1/SvJ * FVB		 MGI:2176162  MGI:97747  MP:0001926 female infertility PMID: 11884400 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001410 head bobbing PMID: 16845470 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0002628 hepatic steatosis PMID: 14603033 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0002628 hepatic steatosis PMID: 14660788 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0002628 hepatic steatosis PMID: 15716267 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0002628 hepatic steatosis PMID: 17003330 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0002628 hepatic steatosis PMID: 17003330 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0002628 hepatic steatosis PMID: 17465682 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0001399 hyperactivity PMID: 19117549 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0001559 hyperglycemia PMID: 17465682 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0001559 hyperglycemia PMID: 17921248 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0001548 hyperlipidemia PMID: 14603033 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0000231 hypertension PMID: 15254591 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0000231 hypertension PMID: 15716267 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0001402 hypoactivity PMID: 17465682 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001525 impaired balance PMID: 16845470 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0005293 impaired glucose tolerance PMID: 14603033 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified		 MGI:97747  MP:0005293 impaired glucose tolerance PMID: 15919792 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0005293 impaired glucose tolerance PMID: 17921248 
Ppargtm1.1Unc Ppargtm1.1Unc/Ppargtm1.1Unc
involves: 129S6/SvEvTac * C57BL/6J		 MGI:97747  MP:0005293 impaired glucose tolerance PMID: 19884495 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0006325 impaired hearing PMID: 16845470 
Atp2b2+|Atp2b2m1Mae|Pparg+|Ppargtm2Mae Atp2b2m1Mae/Atp2b2+,Ppargtm2Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0006325 impaired hearing PMID: 16845470 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001523 impaired righting response PMID: 16845470 
Pparg+|Ppargtm1Mae Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0005292 improved glucose tolerance PMID: 15254591 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0005292 improved glucose tolerance PMID: 14536066 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0005292 improved glucose tolerance PMID: 19117549 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0004892 increased adiponectin level PMID: 14536066 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR		 MGI:97747  MP:0005154 increased B cell proliferation PMID: 10549291 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0005533 increased body temperature PMID: 10549291 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0005533 increased body temperature PMID: 19117549 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0005605 increased bone mass PMID: 15067317 
Ppargtm1.2Mtz|Tg(Fabp4-cre/ERT2)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6		 MGI:2450254  MGI:97747  MP:0009124 increased brown fat cell lipid droplet size PMID: 15070754 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0009119 increased brown fat cell size PMID: 14660788 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0009119 increased brown fat cell size PMID: 17921248 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0009119 increased brown fat cell size PMID: 17921248 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0005343 increased circulating aspartate transaminase level PMID: 14603033 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0005178 increased circulating cholesterol level PMID: 17921248 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0001554 increased circulating free fatty acid level PMID: 14603033 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0001554 increased circulating free fatty acid level PMID: 15716267 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0001554 increased circulating free fatty acid level PMID: 17465682 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0001554 increased circulating free fatty acid level PMID: 17921248 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0005559 increased circulating glucose level PMID: 17003330 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified		 MGI:97747  MP:0005559 increased circulating glucose level PMID: 15919792 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0005559 increased circulating glucose level PMID: 17465682 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0002079 increased circulating insulin level PMID: 14660788 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0002079 increased circulating insulin level PMID: 15716267 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0002079 increased circulating insulin level PMID: 17003330 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0002079 increased circulating insulin level PMID: 17465682 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0002079 increased circulating insulin level PMID: 17921248 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0002079 increased circulating insulin level PMID: 17921248 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified		 MGI:97747  MP:0005669 increased circulating leptin level PMID: 15919792 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0005669 increased circulating leptin level PMID: 10549291 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0001552 increased circulating triglyceride level PMID: 14603033 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0001552 increased circulating triglyceride level PMID: 17003330 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0001552 increased circulating triglyceride level PMID: 17003330 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0001552 increased circulating triglyceride level PMID: 17465682 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0001552 increased circulating triglyceride level PMID: 17921248 
Pparg+|Ppargtm3Yba Ppargtm3Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0001552 increased circulating triglyceride level PMID: 17921248 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0003911 increased drinking behavior PMID: 17465682 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0003911 increased drinking behavior PMID: 19117549 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR		 MGI:97747  MP:0002493 increased IgG level PMID: 10549291 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR		 MGI:97747  MP:0002494 increased IgM level PMID: 10549291 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0004499 increased incidence of chemically-induced tumors PMID: 15930296 
Pparg+|Ppargtm1Rev Ppargtm1Rev/Pparg+
involves: 129S4/SvJae * C57BL/6J		 MGI:97747  MP:0002891 increased insulin sensitivity PMID: 10675354 
Ppargtm1Laz Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0002891 increased insulin sensitivity PMID: 14536066 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0002891 increased insulin sensitivity PMID: 10549291 
Ppargtm1.1Auw Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Pparg		 MGI:97747  MP:0002891 increased insulin sensitivity PMID: 19117549 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR		 MGI:97747  MP:0008566 increased interferon-gamma secretion PMID: 10549291 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR		 MGI:97747  MP:0008687 increased interleukin-2 secretion PMID: 10549291 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0009294 increased interscapular fat pad weight PMID: 17921248 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0009355 increased liver triglyceride level PMID: 14603033 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0009355 increased liver triglyceride level PMID: 15716267 
Pparg+|Ppargtm1Avp Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0002981 increased liver weight PMID: 17003330 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0002981 increased liver weight PMID: 17003330 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0004988 increased osteoblast cell number PMID: 15067317 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0005458 increased percent body fat PMID: 17465682 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0005659 increased resistance to diet-induced obesity PMID: 10549291 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0002310 increased resistance to hepatic steatosis PMID: 10549291 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0009766 increased sensitivity to xenobiotic induced morbidity/mortality PMID: 15930296 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR		 MGI:97747  MP:0003724 increased susceptibility to induced arthritis PMID: 10549291 
Ppargtm1Rev|Ppargtm2Mae Ppargtm1Rev/Ppargtm2Mae
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J		 MGI:97747  MP:0002842 increased systemic arterial blood pressure PMID: 19884495 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0001759 increased urine glucose level PMID: 17465682 
Ppargtm2Avp Ppargtm2Avp/Ppargtm2Avp
Not Specified		 MGI:97747  MP:0000008 increased white adipose tissue amount PMID: 15919792 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0009118 increased white fat cell size PMID: 14660788 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0005331 insulin resistance PMID: 14603033 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0005331 insulin resistance PMID: 14660788 
Ppargtm1Yec Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6		 MGI:97747  MP:0005331 insulin resistance PMID: 15249658 
Pparg+|Ppargtm1Lja Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ		 MGI:97747  MP:0005331 insulin resistance PMID: 15716267 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0005331 insulin resistance PMID: 17003330 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0005331 insulin resistance PMID: 17465682 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0005331 insulin resistance PMID: 17921248 
Pparg+|Ppargtm1Tka Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA		 MGI:97747  MP:0008541 leukostasis PMID: 17003451 
Ppargtm1.1Mgn Ppargtm1.1Mgn/Ppargtm1.1Mgn
involves: 129S6/SvEvTac * C57BL/6J		 MGI:97747  MP:0002169 no abnormal phenotype detected PMID: 11857800 
Ppargtm1.2Mtz|Tg(KRT14-cre)1Ipc Ppargtm1.2Mtz/Ppargtm1.2Mtz,Tg(KRT14-cre)1Ipc/0
involves: C57BL/6 * SJL		 MGI:2177412  MGI:97747  MP:0002169 no abnormal phenotype detected PMID: 16751185 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0003674 oxidative stress PMID: 17465682 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0009110 pancreas hyperplasia PMID: 17921248 
Ppargtm1.1Gonz|Tg(Ins2-cre)25Mgn Ppargtm1.1Gonz/Ppargtm1.1Gonz,Tg(Ins2-cre)25Mgn/0
involves: 129 * C57 * FVB		 MGI:2176225  MGI:97747  MP:0005491 pancreatic islet hyperplasia PMID: 14517292 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0005491 pancreatic islet hyperplasia PMID: 17921248 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA		 MGI:97747  MP:0001715 placental labyrinth hypoplasia PMID: 10549291 
Lepob|Pparg+|Ppargtm1Avp Lepob/Lepob,Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:104663  MGI:97747  MP:0001433 polyphagia PMID: 17003330 
Lepob|Ppargtm2Avp Lepob/Lepob,Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6		 MGI:104663  MGI:97747  MP:0001433 polyphagia PMID: 17465682 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0001732 postnatal growth retardation PMID: 14603033 
Pparg+|Ppargtm1Uls Ppargtm1Uls/Pparg+
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0001732 postnatal growth retardation PMID: 15231871 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0001732 postnatal growth retardation PMID: 16845470 
Ppargtm1Auw Ppargtm1Auw/Ppargtm1Auw
either: 129/Sv or C57BL/6J or (involves: 129/Sv * C57BL/6J)		 MGI:97747  MP:0002082 postnatal lethality PMID: 14603033 
Ppargtm2Rev|Tg(Fabp4-cre)1Rev Ppargtm2Rev/Ppargtm2Rev,Tg(Fabp4-cre)1Rev/?
involves: 129S4/SvJae * C57BL/6		 MGI:2450253  MGI:97747  MP:0008489 postnatal slow weight gain PMID: 14660788 
Ppargtm1.2Auw Ppargtm1.2Auw/Ppargtm1.2Auw
B6.Cg-Pparg		 MGI:97747  MP:0002083 premature death PMID: 19997628 
Ppargtm1.2Mgn Ppargtm1.2Mgn/Ppargtm1.2Mgn
involves: 129S6/SvEvTac * C57BL/6J		 MGI:97747  MP:0002080 prenatal lethality PMID: 11857800 
Ppargtm1Mae Ppargtm1Mae/Ppargtm1Mae
involves: 129S6/SvEvTac * C57BL/6		 MGI:97747  MP:0002080 prenatal lethality PMID: 15254591 
Ppargtm1Uls Ppargtm1Uls/Ppargtm1Uls
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0002080 prenatal lethality PMID: 15231871 
Ppargtm1Wwah Ppargtm1Wwah/Ppargtm1Wwah
Not Specified		 MGI:97747  MP:0002080 prenatal lethality PMID: 11514592 
Ppargtm1Avp Ppargtm1Avp/Ppargtm1Avp
involves: 129S2/SvPas * C57BL/6		 MGI:97747  MP:0002080 prenatal lethality PMID: 17003330 
Ppargtm1Gonz|Tg(MMTV-cre)1Mam Ppargtm1Gonz/Ppargtm1Gonz,Tg(MMTV-cre)1Mam/?
involves: 129X1/SvJ * FVB		 MGI:2176162  MGI:97747  MP:0001923 reduced female fertility PMID: 11884400 
Pparg+|Ppargtm2Yba Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6		 MGI:97747  MP:0001921 reduced fertility PMID: 17921248 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0010725 thin interventricular septum PMID: 10549290 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0002652 thin myocardium PMID: 10549290 
Ppargtm1Tka Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA		 MGI:97747  MP:0002652 thin myocardium PMID: 10549291 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0010556 thin ventricle myocardium compact layer PMID: 10549290 
Ppargtm1Rev Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae		 MGI:97747  MP:0000280 thin ventricular wall PMID: 10549290 
Atp2b2m1Mae|Ppargtm2Mae Atp2b2m1Mae/Atp2b2m1Mae,Ppargtm2Mae/Ppargtm2Mae
involves: 129S6/SvEvTac * C57BL/6J		 MGI:105368  MGI:97747  MP:0000745 tremors PMID: 16845470 
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Abdominal obesity-metabolic syndrome 1; AOMS1
Synonyms: Metabolic syndrome X [Disease Ontology: DOID:14221]
Disease Ontology: DOID:14221
OMIM: 605552
Comments:  Dominant negative PPAR-gamma mutations in humans result in features associated with metabolic syndrome (severe insulin resistance, dyslipidemia and hypertension).
References:  28,39,70
Disease:  Atherosclerosis susceptibility
Disease Ontology: DOID:1936
OMIM: 108725
Comments:  Alteration at the receptor level: stimulated expression in atherosclerotic lesions, in macrophages and monocytic cell lines
References:  59,103
Disease:  Carotid intimal medial thickness 1
OMIM: 609338
Disease:  Colorectal cancer
Disease Ontology: DOID:9256
OMIM: 114500
Comments:  Human colon cancer is associated with loss-of function mutations in PPAR-gamma ligand-binding domain, potential antitumor efficacity of combining RXR and PPAR-gamma agonist
References:  18,60,111-112
Disease:  Diabetes mellitus, noninsulin-dependent; NIDDM
Synonyms: Diabetes mellitus, Type II; T2D [OMIM: 125853]
Maturity onset diabetes
Type 2 diabetes mellitus [Disease Ontology: DOID:9352]
Disease Ontology: DOID:9352
OMIM: 125853
Comments:  Mutations in the ligand-binding domain are associated with severe insulin resistance, diabetes mellitus and hypertension
References:  4,26,28,49,59
Disease:  Familial partial lipodystrophy associated with PPARG mutations
Synonyms: Familial partial lipodystrophy [Disease Ontology: DOID:0050440]
Lipodystrophy, familial partial, type 3; FPLD3 [OMIM: 604367]
Disease Ontology: DOID:0050440
OMIM: 604367
Orphanet: ORPHA79083
Disease:  Giant cell glioblastoma
Synonyms: Glioma susceptibility 1; GLM1 [OMIM: 137800]
Disease Ontology: DOID:3074
OMIM: 137800
Orphanet: ORPHA251579
Disease:  Glioblastoma
Synonyms: Glioblastoma multiforme
Glioma susceptibility 1; GLM1 [OMIM: 137800]
Disease Ontology: DOID:3068
OMIM: 137800
Orphanet: ORPHA360
Disease:  Gliosarcoma
Disease Ontology: DOID:3071
Orphanet: ORPHA251576
Disease:  Obesity
Disease Ontology: DOID:9970
OMIM: 601665
Comments:  Mutation in the ligand-independent activation domain of PPAR-gamma2 causes overweight, increased level of PPAR-gamma2 mRNA in obese subjects
References:  5,26,33,59,124
Disease:  Prostate cancer
Disease Ontology: DOID:10283
OMIM: 176807
Comments:  PPARgamma is expressed in human prostate adenocarcinomas and cell lines derived from human prostate tumors.
References:  86
Disease:  Thyroid carcinoma, follicular; FTC
Synonyms: Differentiated thyroid carcinoma [Orphanet: ORPHA146]
Follicular thyroid carcinoma [Disease Ontology: DOID:3962]
Disease Ontology: DOID:3962
OMIM: 188470
Orphanet: ORPHA146
Comments:  PAX8-PPAR gamma fusion protein promotes differentiated follicular thyroid neoplasia
References:  21,81,91
Gene Expression and Pathophysiology Click here for help
Disrupted expression in macrophages
Tissue or cell type:  Macrophage
Pathophysiology: 
Species:  Mouse
Technique:  Transgenesis
References:  128
PPAR gamma KO: not viable (defects in placenta formation)
Tissue or cell type: 
Pathophysiology: 
Species:  Mouse
Technique:  Knockout
References:  3
Forced expression in hepatocytes induced the classical pattern of PPAR gamma-mediated gene activation and resulted in steatosis
Tissue or cell type:  Hepatocytes
Pathophysiology:  Steatosis
Species:  Mouse
Technique:  Retroviral mediated gene transfer
References:  137
PPAR gamma conditional KO in white adipocytes
Tissue or cell type: 
Pathophysiology:  Retarded growth, severe lipodystrophy (hypocellularity and hypertrophy) and hyperlipidemia
Species:  Mouse
Technique:  Cre-loxP system
References:  66
PPAR gamma conditional KO in muscle
Tissue or cell type:  Adipose tissue
Pathophysiology:  Progressive insulin resistance combined with increased adipose tissue mass
Species:  Mouse
Technique:  Cre-loxP system
References:  51,92
PPAR gamma conditional KO in adipocytes: lipodystrophy (hypocellularity and hypertrophy), elevated plasma FFAs and TGs, decreased plasma leptin and adiponectin, insuline resistance in fat and liver
Tissue or cell type:  Adipose tissue
Pathophysiology:  Lipodystrophy
Species:  Mouse
Technique:  Cre-loxP system
References:  55
PPAR gamma heterozygous mice
Tissue or cell type: 
Pathophysiology:  Reduced body size and weight, reduced insulin resistance, smaller adipocytes and fat depots
Species:  Mouse
Technique:  Ablation of one allele
References:  67
PPAR gamma conditional KO in pancreatic beta cells
Tissue or cell type:  Pancreatic beta cells
Pathophysiology:  Significant islet hyperplasia on chow diet, blunted expansion of beta-cell mass
Species:  Mouse
Technique:  Cre-loxP system
References:  105
PPAR gamma L466A dominant negative knock-in mutant
Tissue or cell type: 
Pathophysiology: 
Species:  Mouse
Technique:  Knock-in
References:  39
PPAR gamma conditional KO in adipocytes: white and brown adipocytes are replaced by newly formed PPAR gamma positive adipocytes
Tissue or cell type:  Adipose tissue
Pathophysiology: 
Species:  Mouse
Technique:  Tamoxifen-dependent Cre-ERT2 recombination
References:  47
Biologically Significant Variants Click here for help
Type:  Alternative promoters
Species:  Human
Description:  PPAR-gamma3; gives rise to a protein indistinguishable from PPAR-gamma1 from a distinct promotor. Restricted expression, like PPAR-gamma2, to colon and adipose tissue in human
Amino acids:  505
Protein accession:  NP_619725
References:  36
Type:  Splice variant
Species:  Human
Description:  PPAR-gamma2;N-terminus carries 30 additional amino acids encoded by exon B PPAR-gamma2-specific, encoded by 7 exons
Amino acids:  505
Protein accession:  NP_056953
References:  35,42
Type:  Splice variant
Species:  Human
Description:  PPAR-gamma Isoform1; encoded by 8 exons (2 of them PPAR-gamma1-specific)
Amino acids:  477
Protein accession:  NP_619725
References:  35,42,145
Type:  Splice variant
Species:  Human
Description:  gammaORF4: readthrough in intron 4, encoded protein lacks the LBD, dominant negative versus PPAR-gamma, expressed in tumor cell lines and tissues
References:  107
General Comments
PPARγ is being examined as a therapeutic target whose pharmacological activation may provide clinically beneficial neuroprotective effects [23,69].

References

Show »

1. Acton 3rd JJ, Black RM, Jones AB, Moller DE, Colwell L, Doebber TW, Macnaul KL, Berger J, Wood HB. (2005) Benzoyl 2-methyl indoles as selective PPARgamma modulators. Bioorg Med Chem Lett, 15 (2): 357-62. [PMID:15603954]

2. Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN. (2002) Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol, 61 (1): 7-12. [PMID:11752200]

3. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM. (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell, 4 (4): 585-95. [PMID:10549290]

4. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature, 402 (6764): 880-3. [PMID:10622252]

5. Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR. (1998) Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes, 47 (11): 1806-8. [PMID:9792554]

6. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD. (1996) Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology, 137 (10): 4189-95. [PMID:8828476]

7. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, Moller DE. (1999) Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem, 274 (10): 6718-25. [PMID:10037770]

8. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE. (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol, 17 (4): 662-76. [PMID:12554792]

9. Bishop-Bailey D, Hla T, Warner TD. (2000) Bisphenol A diglycidyl ether (BADGE) is a PPARgamma agonist in an ECV304 cell line. Br J Pharmacol, 131 (4): 651-4. [PMID:11030710]

10. Boubia B, Poupardin O, Barth M, Binet J, Peralba P, Mounier L, Jacquier E, Gauthier E, Lepais V, Chatar M et al.. (2018) Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. J Med Chem, 61 (6): 2246-2265. [PMID:29446942]

11. Brooks DA, Etgen GJ, Rito CJ, Shuker AJ, Dominianni SJ, Warshawsky AM, Ardecky R, Paterniti JR, Tyhonas J, Karanewsky DS, Kauffman RF, Broderick CL, Oldham BA, Montrose-Rafizadeh C, Winneroski LL, Faul MM, McCarthy JR. (2001) Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. J Med Chem, 44 (13): 2061-4. [PMID:11405642]

12. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM. (1999) A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes, 48 (7): 1415-24. [PMID:10389847]

13. Brown PJ, Stuart LW, Hurley KP, Lewis MC, Winegar DA, Wilson JG, Wilkison WO, Ittoop OR, Willson TM. (2001) Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med Chem Lett, 11 (9): 1225-7. [PMID:11354382]

14. Calleri E, Pochetti G, Dossou KS, Laghezza A, Montanari R, Capelli D, Prada E, Loiodice F, Massolini G, Bernier M et al.. (2014) Resveratrol and its metabolites bind to PPARs. Chembiochem, 15 (8): 1154-60. [PMID:24796862]

15. Carley AN, Semeniuk LM, Shimoni Y, Aasum E, Larsen TS, Berger JP, Severson DL. (2004) Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function. Am J Physiol Endocrinol Metab, 286 (3): E449-55. [PMID:14600074]

16. Castillo G, Brun RP, Rosenfield JK, Hauser S, Park CW, Troy AE, Wright ME, Spiegelman BM. (1999) An adipogenic cofactor bound by the differentiation domain of PPARgamma. EMBO J, 18 (13): 3676-87. [PMID:10393183]

17. Cesario RM, Klausing K, Razzaghi H, Crombie D, Rungta D, Heyman RA, Lala DS. (2001) The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol, 15 (8): 1360-9. [PMID:11463859]

18. Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW. (2006) Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Lett, 240 (2): 225-33. [PMID:16271436]

19. Chakrabarti R, Misra P, Vikramadithyan RK, Premkumar M, Hiriyan J, Datla SR, Damarla RK, Suresh J, Rajagopalan R. (2004) Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol, 491 (2-3): 195-206. [PMID:15140637]

20. Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, Gershome C, Suresh J, Rajagopalan R. (2003) Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol, 140 (3): 527-37. [PMID:12970088]

21. Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, Wentworth J, Philips J, Clifton-Bligh R, Robinson BG. (2003) Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab, 88 (1): 354-7. [PMID:12519876]

22. Cobb JE, Blanchard SG, Boswell EG, Brown KK, Charifson PS, Cooper JP, Collins JL, Dezube M, Henke BR, Hull-Ryde EA, Lake DH, Lenhard JM, Oliver W, Oplinger J, Pentti M, Parks DJ, Plunket KD, Tong WQ. (1998) N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. J Med Chem, 41 (25): 5055-69. [PMID:9836622]

23. Corona JC, Duchen MR. (2016) PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic Biol Med, 100: 153-163. [PMID:27352979]

24. Debril MB, Dubuquoy L, Feige JN, Wahli W, Desvergne B, Auwerx J, Gelman L. (2005) Scaffold attachment factor B1 directly interacts with nuclear receptors in living cells and represses transcriptional activity. J Mol Endocrinol, 35 (3): 503-17. [PMID:16326836]

25. Debril MB, Gelman L, Fayard E, Annicotte JS, Rocchi S, Auwerx J. (2004) Transcription factors and nuclear receptors interact with the SWI/SNF complex through the BAF60c subunit. J Biol Chem, 279 (16): 16677-86. [PMID:14701856]

26. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet, 20 (3): 284-7. [PMID:9806549]

27. Del Rio C, Cantarero I, Palomares B, Gómez-Cañas M, Fernández-Ruiz J, Pavicic C, García-Martín A, Luz Bellido M, Ortega-Castro R, Pérez-Sánchez C et al.. (2018) VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways. Br J Pharmacol, 175 (19): 3813-3831. [PMID:30033591]

28. Desvergne B, Michalik L, Wahli W. (2004) Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol, 18 (6): 1321-32. [PMID:15087471]

29. Desvergne B, Wahli W. (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev, 20 (5): 649-88. [PMID:10529898]

30. Dietz M, Mohr P, Kuhn B, Maerki HP, Hartman P, Ruf A, Benz J, Grether U, Wright MB. (2012) Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem, 7 (6): 1101-11. [PMID:22489042]

31. Doebber TW, Kelly LJ, Zhou G, Meurer R, Biswas C, Li Y, Wu MS, Ippolito MC, Chao YS, Wang PR, Wright SD, Moller DE, Berger JP. (2004) MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities. Biochem Biophys Res Commun, 318 (2): 323-8. [PMID:15120604]

32. Ebdrup S, Pettersson I, Rasmussen HB, Deussen HJ, Frost Jensen A, Mortensen SB, Fleckner J, Pridal L, Nygaard L, Sauerberg P. (2003) Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. J Med Chem, 46 (8): 1306-17. [PMID:12672231]

33. Ek J, Urhammer SA, Sørensen TI, Andersen T, Auwerx J, Pedersen O. (1999) Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia, 42 (7): 892-5. [PMID:10440134]

34. Elbrecht A, Chen Y, Adams A, Berger J, Griffin P, Klatt T, Zhang B, Menke J, Zhou G, Smith RG, Moller DE. (1999) L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. J Biol Chem, 274 (12): 7913-22. [PMID:10075686]

35. Fajas L, Auboeuf D, Raspé E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem, 272 (30): 18779-89. [PMID:9228052]

36. Fajas L, Fruchart JC, Auwerx J. (1998) PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett, 438 (1-2): 55-60. [PMID:9821958]

37. Ferry G, Bruneau V, Beauverger P, Goussard M, Rodriguez M, Lamamy V, Dromaint S, Canet E, Galizzi JP, Boutin JA. (2001) Binding of prostaglandins to human PPARgamma: tool assessment and new natural ligands. Eur J Pharmacol, 417 (1-2): 77-89. [PMID:11301062]

38. Forman BM. (2002) The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem, 277 (15): 12503-6. [PMID:11877384]

39. Freedman BD, Lee EJ, Park Y, Jameson JL. (2005) A dominant negative peroxisome proliferator-activated receptor-gamma knock-in mouse exhibits features of the metabolic syndrome. J Biol Chem, 280 (17): 17118-25. [PMID:15716267]

40. Frohnert BI, Hui TY, Bernlohr DA. (1999) Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J Biol Chem, 274 (7): 3970-7. [PMID:9933587]

41. Gelman L, Zhou G, Fajas L, Raspé E, Fruchart JC, Auwerx J. (1999) p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J Biol Chem, 274 (12): 7681-8. [PMID:10075656]

42. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD. (1995) Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr, 4 (4-5): 281-99. [PMID:7787419]

43. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. (2005) Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev, 19 (4): 453-61. [PMID:15681609]

44. Guardiola-Diaz HM, Rehnmark S, Usuda N, Albrektsen T, Feltkamp D, Gustafsson JA, Alexson SE. (1999) Rat peroxisome proliferator-activated receptors and brown adipose tissue function during cold acclimatization. J Biol Chem, 274 (33): 23368-77. [PMID:10438514]

45. Guo Q, Sahoo SP, Wang PR, Milot DP, Ippolito MC, Wu MS, Baffic J, Biswas C, Hernandez M, Lam MH, Sharma N, Han W, Kelly LJ, MacNaul KL, Zhou G, Desai R, Heck JV, Doebber TW, Berger JP, Moller DE, Sparrow CP, Chao YS, Wright SD. (2004) A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology, 145 (4): 1640-8. [PMID:14701675]

46. Hanke T, Cheung SY, Kilu W, Heering J, Ni X, Planz V, Schierle S, Faudone G, Friedrich M, Wanior M et al.. (2020) A Selective Modulator of Peroxisome Proliferator-Activated Receptor γ with an Unprecedented Binding Mode. J Med Chem, 63 (9): 4555-4561. [PMID:32267688]

47. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM. (2003) Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA, 100 (26): 15712-7. [PMID:14660788]

48. Heinlein CA, Ting HJ, Yeh S, Chang C. (1999) Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma. J Biol Chem, 274 (23): 16147-52. [PMID:10347167]

49. Henke BR. (2004) Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. J Med Chem, 47 (17): 4118-27. [PMID:15293980]

50. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA, Noble SA, Oliver W, Parks DJ, Plunket KD, Szewczyk JR, Willson TM. (1998) N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem, 41 (25): 5020-36. [PMID:9836620]

51. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J. (2003) Muscle-specific Pparg deletion causes insulin resistance. Nat Med, 9 (12): 1491-7. [PMID:14625542]

52. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB. (2005) TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science, 309 (5737): 1074-8. [PMID:16099986]

53. Huss JM, Kopp RP, Kelly DP. (2002) Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha. J Biol Chem, 277 (43): 40265-74. [PMID:12181319]

54. Huss JM, Torra IP, Staels B, Giguère V, Kelly DP. (2004) Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol, 24 (20): 9079-91. [PMID:15456881]

55. Imai T, Takakuwa R, Marchand S, Dentz E, Bornert JM, Messaddeq N, Wendling O, Mark M, Desvergne B, Wahli W, Chambon P, Metzger D. (2004) Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci USA, 101 (13): 4543-7. [PMID:15070754]

56. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. (1997) The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol, 11 (6): 693-705. [PMID:9171233]

57. Jaradat MS, Wongsud B, Phornchirasilp S, Rangwala SM, Shams G, Sutton M, Romstedt KJ, Noonan DJ, Feller DR. (2001) Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol, 62 (12): 1587-95. [PMID:11755111]

58. Kamei Y, Ohizumi H, Fujitani Y, Nemoto T, Tanaka T, Takahashi N, Kawada T, Miyoshi M, Ezaki O, Kakizuka A. (2003) PPARgamma coactivator 1beta/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity. Proc Natl Acad Sci USA, 100 (21): 12378-83. [PMID:14530391]

59. Kersten S, Desvergne B, Wahli W. (2000) Roles of PPARs in health and disease. Nature, 405 (6785): 421-4. [PMID:10839530]

60. Kim E, Chen F, Wang CC, Harrison LE. (2006) CDK5 is a novel regulatory protein in PPARgamma ligand-induced antiproliferation. Int J Oncol, 28 (1): 191-4. [PMID:16327995]

61. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell, 83 (5): 813-9. [PMID:8521498]

62. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA, 94 (9): 4318-23. [PMID:9113987]

63. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature, 358 (6389): 771-4. [PMID:1324435]

64. Knutti D, Kralli A. (2001) PGC-1, a versatile coactivator. Trends Endocrinol Metab, 12 (8): 360-5. [PMID:11551810]

65. Kojo H, Fukagawa M, Tajima K, Suzuki A, Fujimura T, Aramori I, Hayashi K, Nishimura S. (2003) Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPAR delta(beta). J Pharmacol Sci, 93 (3): 347-55. [PMID:14646253]

66. Koutnikova H, Cock TA, Watanabe M, Houten SM, Champy MF, Dierich A, Auwerx J. (2003) Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci USA, 100 (24): 14457-62. [PMID:14603033]

67. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T. (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell, 4 (4): 597-609. [PMID:10549291]

68. Laplante M, Sell H, MacNaul KL, Richard D, Berger JP, Deshaies Y. (2003) PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes, 52 (2): 291-9. [PMID:12540599]

69. Lecca D, Janda E, Mulas G, Diana A, Martino C, Angius F, Spolitu S, Casu MA, Simbula G, Boi L et al.. (2018) Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease models. Br J Pharmacol, 175 (16): 3298-3314. [PMID:29570770]

70. Lee CH, Olson P, Evans RM. (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology, 144 (6): 2201-7. [PMID:12746275]

71. Lee G, Elwood F, McNally J, Weiszmann J, Lindstrom M, Amaral K, Nakamura M, Miao S, Cao P, Learned RM et al.. (2002) T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem, 277 (22): 19649-57. [PMID:11877444]

72. Leers J, Treuter E, Gustafsson JA. (1998) Mechanistic principles in NR box-dependent interaction between nuclear hormone receptors and the coactivator TIF2. Mol Cell Biol, 18 (10): 6001-13. [PMID:9742117]

73. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM, Blanchard SG. (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry, 41 (21): 6640-50. [PMID:12022867]

74. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem, 272 (6): 3406-10. [PMID:9013583]

75. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem, 270 (22): 12953-6. [PMID:7768881]

76. Lemon B, Inouye C, King DS, Tjian R. (2001) Selectivity of chromatin-remodelling cofactors for ligand-activated transcription. Nature, 414 (6866): 924-8. [PMID:11780067]

77. Li PP, Shan S, Chen YT, Ning ZQ, Sun SJ, Liu Q, Lu XP, Xie MZ, Shen ZF. (2006) The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Br J Pharmacol, 148 (5): 610-8. [PMID:16751799]

78. Lin HR. (2012) Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists. Bioorg Med Chem Lett, 22 (8): 2954-8. [PMID:22424975]

79. Liu KG, Lambert MH, Ayscue AH, Henke BR, Leesnitzer LM, Oliver WR, Plunket KD, Xu HE, Sternbach DD, Willson TM. (2001) Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight. Bioorg Med Chem Lett, 11: 3111-3113. [PMID:11720854]

80. Marciano DP, Kuruvilla DS, Pascal BD, Griffin PR. (2015) Identification of Bexarotene as a PPARγ Antagonist with HDX. PPAR Res, 2015: 254560. [PMID:26451138]

81. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V. (2002) Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab, 87 (8): 3947-52. [PMID:12161538]

82. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem, 272 (45): 28210-7. [PMID:9353271]

83. Misra P, Chakrabarti R, Vikramadithyan RK, Bolusu G, Juluri S, Hiriyan J, Gershome C, Rajjak A, Kashireddy P, Yu S, Surapureddi S, Qi C, Zhu YJ, Rao MS, Reddy JK, Ramanujam R. (2003) PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. J Pharmacol Exp Ther, 306 (2): 763-71. [PMID:12730351]

84. Mizukami J, Taniguchi T. (1997) The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP. Biochem Biophys Res Commun, 240 (1): 61-4. [PMID:9367882]

85. Molnár F, Matilainen M, Carlberg C. (2005) Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. J Biol Chem, 280 (28): 26543-56. [PMID:15888456]

86. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. (2000) Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA, 97 (20): 10990-5. [PMID:10984506]

87. Murakami K, Ide T, Suzuki M, Mochizuki T, Kadowaki T. (1999) Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. Biochem Biophys Res Commun, 260 (3): 609-13. [PMID:10403814]

88. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadowaki T. (1998) A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes, 47 (12): 1841-7. [PMID:9836514]

89. Nevin DK, Peters MB, Carta G, Fayne D, Lloyd DG. (2012) Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds. J Med Chem, 55 (11): 4978-89. [PMID:22582973]

90. Nichols JS, Parks DJ, Consler TG, Blanchard SG. (1998) Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain. Anal Biochem, 257 (2): 112-9. [PMID:9514791]

91. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, Kroll TG, Nikiforov YE. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab, 88 (5): 2318-26. [PMID:12727991]

92. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR. (2003) Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest, 112 (4): 608-18. [PMID:12925701]

93. Nosjean O, Boutin JA. (2002) Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part?. Cell Signal, 14 (7): 573-83. [PMID:11955950]

94. O'Mahony G, Petersen J, Ek M, Rae R, Johansson C, Jianming L, Prokoph N, Bergström F, Bamberg K, Giordanetto F et al.. (2022) Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation. ACS Medicinal Chemistry Letters, 13 (4): 681–686. DOI: 10.1021/acsmedchemlett.1c00715

95. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB, Milburn MV, Kliewer SA, Willson TM. (1999) A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA, 96 (11): 6102-6. [PMID:10339548]

96. Oberkofler H, Esterbauer H, Linnemayr V, Strosberg AD, Krempler F, Patsch W. (2002) Peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 recruitment regulates PPAR subtype specificity. J Biol Chem, 277 (19): 16750-7. [PMID:11875072]

97. Pickavance LC, Brand CL, Wassermann K, Wilding JP. (2005) The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol, 144 (3): 308-16. [PMID:15655531]

98. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell, 92 (6): 829-39. [PMID:9529258]

99. Qi C, Chang J, Zhu Y, Yeldandi AV, Rao SM, Zhu YJ. (2002) Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor alpha. J Biol Chem, 277 (32): 28624-30. [PMID:12039952]

100. Qi C, Surapureddi S, Zhu YJ, Yu S, Kashireddy P, Rao MS, Reddy JK. (2003) Transcriptional coactivator PRIP, the peroxisome proliferator-activated receptor gamma (PPARgamma)-interacting protein, is required for PPARgamma-mediated adipogenesis. J Biol Chem, 278 (28): 25281-4. [PMID:12754253]

101. Qi C, Zhu Y, Reddy JK. (2000) Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys, 32 Spring: 187-204. [PMID:11330046]

102. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, Lazar MA. (1998) A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem, 273 (49): 32679-84. [PMID:9830009]

103. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. (1998) Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA, 95 (13): 7614-9. [PMID:9636198]

104. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, Leesnitzer LM, Blanchard SG, Desreumaux P, Moras D, Renaud JP, Auwerx J. (2001) A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell, 8 (4): 737-47. [PMID:11684010]

105. Rosen ED, Kulkarni RN, Sarraf P, Ozcan U, Okada T, Hsu CH, Eisenman D, Magnuson MA, Gonzalez FJ, Kahn CR, Spiegelman BM. (2003) Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol, 23 (20): 7222-9. [PMID:14517292]

106. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P. (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med, 201 (8): 1205-15. [PMID:15824083]

107. Sabatino L, Casamassimi A, Peluso G, Barone MV, Capaccio D, Migliore C, Bonelli P, Pedicini A, Febbraro A, Ciccodicola A, Colantuoni V. (2005) A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing. J Biol Chem, 280 (28): 26517-25. [PMID:15857827]

108. Sahebkar A, Chew GT, Watts GF. (2014) New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother, 15 (4): 493-503. [PMID:24428677]

109. Sakamoto J, Kimura H, Moriyama S, Imoto H, Momose Y, Odaka H, Sawada H. (2004) A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol, 495 (1): 17-26. [PMID:15219816]

110. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H. (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun, 278 (3): 704-11. [PMID:11095972]

111. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C. (1999) Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell, 3 (6): 799-804. [PMID:10394368]

112. Sasaki T, Fujii K, Yoshida K, Shimura H, Sasahira T, Ohmori H, Kuniyasu H. (2006) Peritoneal metastasis inhibition by linoleic acid with activation of PPARgamma in human gastrointestinal cancer cells. Virchows Arch, 448 (4): 422-7. [PMID:16362414]

113. Schierle S, Flauaus C, Heitel P, Willems S, Schmidt J, Kaiser A, Weizel L, Goebel T, Kahnt AS, Geisslinger G et al.. (2018) Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology. J Med Chem, 61 (13): 5758-5764. [PMID:29878767]

114. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J, 15 (19): 5336-48. [PMID:8895578]

115. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, Auwerx J. (1995) Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem, 270 (33): 19269-76. [PMID:7642600]

116. Sears IB, MacGinnitie MA, Kovacs LG, Graves RA. (1996) Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma. Mol Cell Biol, 16 (7): 3410-9. [PMID:8668156]

117. Shao W, Halachmi S, Brown M. (2002) ERAP140, a conserved tissue-specific nuclear receptor coactivator. Mol Cell Biol, 22 (10): 3358-72. [PMID:11971969]

118. Shibata T, Matsui K, Nagao K, Shinkai H, Yonemori F, Wakitani K. (1999) Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol, 364 (2-3): 211-9. [PMID:9932726]

119. Soares AF, Nosjean O, Cozzone D, D'Orazio D, Becchi M, Guichardant M, Ferry G, Boutin JA, Lagarde M, Géloën A. (2005) Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARgamma. Biochem Biophys Res Commun, 337 (2): 521-5. [PMID:16198309]

120. Tien ES, Davis JW, Vanden Heuvel JP. (2004) Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor alpha coregulator. J Biol Chem, 279 (23): 24053-63. [PMID:15051727]

121. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev, 8 (10): 1224-34. [PMID:7926726]

122. Tontonoz P, Hu E, Spiegelman BM. (1995) Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev, 5 (5): 571-6. [PMID:8664544]

123. Treuter E, Albrektsen T, Johansson L, Leers J, Gustafsson JA. (1998) A regulatory role for RIP140 in nuclear receptor activation. Mol Endocrinol, 12 (6): 864-81. [PMID:9626662]

124. Valve R, Sivenius K, Miettinen R, Pihlajamäki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso M. (1999) Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab, 84 (10): 3708-12. [PMID:10523018]

125. Vikramadithyan RK, Chakrabarti R, Misra P, Premkumar M, Kumar SK, Rao CS, Ghosh A, Reddy KN, Uma C, Rajagopalan R. (2000) Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity. Metab Clin Exp, 49 (11): 1417-23. [PMID:11092504]

126. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J. (1995) Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest, 96 (2): 741-50. [PMID:7635967]

127. Wang Y, Porter WW, Suh N, Honda T, Gribble GW, Leesnitzer LM, Plunket KD, Mangelsdorf DJ, Blanchard SG, Willson TM, Sporn MB. (2000) A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol, 14 (10): 1550-6. [PMID:11043571]

128. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. (2003) PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci USA, 100 (11): 6712-7. [PMID:12740443]

129. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM. (2000) A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem, 275 (3): 1873-7. [PMID:10636887]

130. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT, McKee DD, Moore JT, Willson TM. (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA, 98 (24): 13919-24. [PMID:11698662]

131. Xu Y, Rito CJ, Etgen GJ, Ardecky RJ, Bean JS, Bensch WR, Bosley JR, Broderick CL, Brooks DA, Dominianni SJ, Hahn PJ, Liu S, Mais DE, Montrose-Rafizadeh C, Ogilvie KM, Oldham BA, Peters M, Rungta DK, Shuker AJ, Stephenson GA, Tripp AE, Wilson SB, Winneroski LL, Zink R, Kauffman RF, McCarthy JR. (2004) Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists. J Med Chem, 47 (10): 2422-5. [PMID:15115385]

132. Xue B, Coulter A, Rim JS, Koza RA, Kozak LP. (2005) Transcriptional synergy and the regulation of Ucp1 during brown adipocyte induction in white fat depots. Mol Cell Biol, 25 (18): 8311-22. [PMID:16135818]

133. Yang W, Rachez C, Freedman LP. (2000) Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators. Mol Cell Biol, 20 (21): 8008-17. [PMID:11027271]

134. Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KW, Mossakowska D, Murphy GJ, Roxbee Cox L, Smith SA. (1998) Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther, 284 (2): 751-9. [PMID:9454824]

135. Yu C, Chen L, Luo H, Chen J, Cheng F, Gui C, Zhang R, Shen J, Chen K, Jiang H, Shen X. (2004) Binding analyses between Human PPARgamma-LBD and ligands. Eur J Biochem, 271 (2): 386-97. [PMID:14717706]

136. Yu C, Markan K, Temple KA, Deplewski D, Brady MJ, Cohen RN. (2005) The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis. J Biol Chem, 280 (14): 13600-5. [PMID:15691842]

137. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ, Reddy JK. (2003) Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem, 278 (1): 498-505. [PMID:12401792]

138. Zamir I, Harding HP, Atkins GB, Hörlein A, Glass CK, Rosenfeld MG, Lazar MA. (1996) A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol Cell Biol, 16 (10): 5458-65. [PMID:8816459]

139. Zhang R, Wang A, DeAngelis A, Pelton P, Xu J, Zhu P, Zhou L, Demarest K, Murray WV, Kuo GH. (2007) Discovery of para-alkylthiophenoxyacetic acids as a novel series of potent and selective PPARdelta agonists. Bioorg Med Chem Lett, 17 (14): 3855-9. [PMID:17524639]

140. Zhou G, Cummings R, Li Y, Mitra S, Wilkinson HA, Elbrecht A, Hermes JD, Schaeffer JM, Smith RG, Moller DE. (1998) Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer. Mol Endocrinol, 12 (10): 1594-604. [PMID:9773982]

141. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy JK. (1993) Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem, 268 (36): 26817-20. [PMID:8262913]

142. Zhu Y, Kan L, Qi C, Kanwar YS, Yeldandi AV, Rao MS, Reddy JK. (2000) Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem, 275 (18): 13510-6. [PMID:10788465]

143. Zhu Y, Qi C, Cao WQ, Yeldandi AV, Rao MS, Reddy JK. (2001) Cloning and characterization of PIMT, a protein with a methyltransferase domain, which interacts with and enhances nuclear receptor coactivator PRIP function. Proc Natl Acad Sci USA, 98 (18): 10380-5. [PMID:11517327]

144. Zhu Y, Qi C, Jain S, Rao MS, Reddy JK. (1997) Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem, 272 (41): 25500-6. [PMID:9325263]

145. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, Reddy JK. (1995) Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA, 92 (17): 7921-5. [PMID:7644514]

146. (1988) Bombesin-like peptides in health and disease. Proceedings of an international symposium. October 13-16, 1987, Rome, Italy. A tribute to Vittorio Erspamer, M.D. Ann NY Acad Sci, 547: 1-541. [PMID:3071214]

How to cite this page

1C. Peroxisome proliferator-activated receptors: Peroxisome proliferator-activated receptor-γ. Last modified on 09/06/2023. Accessed on 25/04/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=595.